|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:CASNumber
|
1355326-35-0
|
|
gptkbp:chemicalFormula
|
C23H19F3N6O2
|
|
gptkbp:clinicalTrialPhase
|
Phase 2
|
|
gptkbp:developedBy
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Day_One_Biopharmaceuticals
|
|
gptkbp:hasFDAFastTrackDesignation
|
yes
|
|
gptkbp:hasInChIKey
|
QJQJQJQJQJQJQJ-QJQJQJQJSA-N
|
|
gptkbp:hasOrphanDrugDesignation
|
yes
|
|
gptkbp:hasSMILES
|
C1=CC=C(C=C1)C2=NC3=CC=CC=C3N=C2N4C=NC(=C4C5=CC=C(C=C5)F)C(=O)NC6=CC=C(C=C6)F
|
|
gptkbp:hasUNII
|
6Q1K1Q1K0E
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tovorafenib
|
|
gptkbp:indication
|
pediatric low-grade glioma
solid tumors with RAF alterations
|
|
gptkbp:mechanismOfAction
|
RAF kinase inhibitor
|
|
gptkbp:molecularWeight
|
468.43 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3544947
71587753
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:status
|
investigational
|
|
gptkbp:synonym
|
gptkb:DAY101
gptkb:RAFI-M
gptkb:TAK-580
|
|
gptkbp:target
|
gptkb:ARAF
gptkb:BRAF
gptkb:CRAF
pan-RAF kinase
|
|
gptkbp:bfsParent
|
gptkb:Day_One_Biopharmaceuticals
|
|
gptkbp:bfsLayer
|
7
|